Deepika Jalota Sells 7,218 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) insider Deepika Jalota sold 7,218 shares of PMV Pharmaceuticals stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $1.50, for a total value of $10,827.00. Following the sale, the insider now owns 118,283 shares of the company’s stock, valued at approximately $177,424.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

PMV Pharmaceuticals Stock Up 1.3 %

Shares of PMVP stock opened at $1.51 on Friday. The firm has a market cap of $77.80 million, a P/E ratio of -1.14 and a beta of 1.52. The business has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $1.70. PMV Pharmaceuticals, Inc. has a 12-month low of $1.18 and a 12-month high of $6.98.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.32. As a group, research analysts expect that PMV Pharmaceuticals, Inc. will post -1.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $5.75.

Hedge Funds Weigh In On PMV Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in PMVP. Acadian Asset Management LLC increased its stake in PMV Pharmaceuticals by 170.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,080,194 shares of the company’s stock worth $3,533,000 after purchasing an additional 1,311,745 shares during the period. Opaleye Management Inc. purchased a new position in shares of PMV Pharmaceuticals in the first quarter worth $802,000. Jacobs Levy Equity Management Inc. raised its holdings in PMV Pharmaceuticals by 92.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 826,704 shares of the company’s stock valued at $1,405,000 after buying an additional 397,062 shares during the last quarter. Sectoral Asset Management Inc. raised its holdings in PMV Pharmaceuticals by 125.8% during the 4th quarter. Sectoral Asset Management Inc. now owns 685,985 shares of the company’s stock valued at $2,127,000 after buying an additional 382,161 shares during the last quarter. Finally, Personal CFO Solutions LLC boosted its position in PMV Pharmaceuticals by 57.1% during the 4th quarter. Personal CFO Solutions LLC now owns 550,342 shares of the company’s stock valued at $1,706,000 after buying an additional 200,000 shares during the period. Institutional investors own 90.20% of the company’s stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.